The DOI matches its Crossref record; 565 of the 565 references it cites were found in a registry or an index.
2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception
Open accessAbstract
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD). The initial study, ADNI-1, enrolled 400 subjects with early mild cognitive impairment (MCI), 200 with early AD, and 200 cognitively normal elderly controls. ADNI-1 was extended by a 2-year Grand Opportunities grant in 2009 and by a competitive renewal, ADNI-2, which enrolled an additional 550 participants and will run until 2015. This article reviews all papers published since the inception of the initiative and summarizes the results to the end of 2013. The major accomplishments of ADNI have been as follows: (1) the development of standardized methods for clinical tests, magnetic resonance imaging (MRI), positron emission tomography (PET), and cerebrospinal fluid (CSF) biomarkers in a multicenter setting; (2) elucidation of the patterns and rates of change of imaging and CSF biomarker measurements in control subjects, MCI patients, and AD patients. CSF biomarkers are largely consistent with disease trajectories predicted by β-amyloid cascade (Hardy, J Alzheimer's Dis 2006;9(Suppl 3):151-3) and tau-mediated neurodegeneration hypotheses for AD, whereas brain atrophy and hypometabolism levels show predicted patterns but exhibit differing rates of change depending on region and disease severity; (3) the assessment of alternative methods of diagnostic categorization. Currently, the best classifiers select and combine optimum features from multiple modalities, including MRI, [(18)F]-fluorodeoxyglucose-PET, amyloid PET, CSF biomarkers, and clinical tests; (4) the development of blood biomarkers for AD as potentially noninvasive and low-cost alternatives to CSF biomarkers for AD diagnosis and the assessment of α-syn as an additional biomarker; (5) the development of methods for the early detection of AD. CSF biomarkers, β-amyloid 42 and tau, as well as amyloid PET may reflect the earliest steps in AD pathology in mildly symptomatic or even nonsymptomatic subjects and are leading candidates for the detection of AD in its preclinical stages; (6) the improvement of clinical trial efficiency through the identification of subjects most likely to undergo imminent future clinical decline and the use of more sensitive outcome measures to reduce sample sizes. Multimodal methods incorporating APOE status and longitudinal MRI proved most highly predictive of future decline. Refinements of clinical tests used as outcome measures such as clinical dementia rating-sum of boxes further reduced sample sizes; (7) the pioneering of genome-wide association studies that leverage quantitative imaging and biomarker phenotypes, including longitudinal data, to confirm recently identified loci, CR1, CLU, and PICALM and to identify novel AD risk loci; (8) worldwide impact through the establishment of ADNI-like programs in Japan, Australia, Argentina, Taiwan, China, Korea, Europe, and Italy; (9) understanding the biology and pathobiology of normal aging, MCI, and AD through integration of ADNI biomarker and clinical data to stimulate research that will resolve controversies about competing hypotheses on the etiopathogenesis of AD, thereby advancing efforts to find disease-modifying drugs for AD; and (10) the establishment of infrastructure to allow sharing of all raw and processed data without embargo to interested scientific investigators throughout the world.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SNPs in and around candidate genes including APOE, BIN1, SORL1, and CR1 have been associated with traits including medial temporal lobe atrophy and cortical thickness [225–228]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [225]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease
Rhinn, H., Fujita, R., Qiang, L., Cheng, R., Lee, J. H., & Abeliovich, A. (2013) · Nature · doi:10.1038/nature12415 · Cited by 151
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“Diagnosis of MCI using National Institute on AgingAlzheimer’s Association criteria The NIA-AA criteria for MCI due to AD recently incorporated the use of biomarkers for both amyloid deposition (CSF Ab42, (11)C-PiB-PET) and neuronal injury (CSF tau, hippocampal and whole brain atrophy on MRI, FDG-PET) in addition to cl…”
MethodSelf-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Self-citationda Luz, A. C. D. D. S., Dias, G. P., Bevilaqua, M. C. D. N., Cocks, G. D., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 4,015
Research works printed but not linked: 14
- Trojanowski J, 2004, Searching for the biomarkers of Alzheimer's, Pract Neurol, 3, 30
- Mueller SG, 2006, Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative, Cogn Dement, 5, 56
- Cruchaga C, 2009, SNPs in the regulatory subunit of calcineurin are associated with CSF tau protein levels, brain mRNA levels, Alzheimers Dement, 5, P471
- LiY WangY WuG ShiF ZhouL LinW et al.Discriminant analysis of longitudinal cortical thickness changes in Alzheimer's disease using dynamic and network features.Neurobiol Aging (in press).
- Thambisetty M, 2012, Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification byAPOEGenotype, Biol Psychiatry, 73, 334
- Weiner MW, 2012, The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception, Alzheimers Dement, 8, S1
- 10.1016/j.bbadis.2011.09.008 · DOI
- 10.1016/j.neuroimage.2009.05.056 · DOI
- 10.3389/fnins.2012.00115 · DOI
- 10.1007/s11682-012-9184-1 · DOI
- 10.1007/s11682-012-9196-x · DOI
- 10.3389/fgene.2011.00073 · DOI
- 10.1016/j.neuroimage.2011.03.077 · DOI
- 10.2174/156720512802455331 · DOI
Cited by
Sorted by citations
Items 101–200 of 348
Amyloid PET Quantification Via End-to-End Training of a Deep Learning
Initiative, A. D. N., Kim, J. Y., Suh, H. Y., Ryoo, H. G., Oh, D., Choi, H., Paeng, J. C., Cheon, G. J., Kang, K. W., & Lee, D. S. (2019) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-019-00610-0 · Cited by 34
Self-citationExploring and visualizing multidimensional data in translational research platforms
Dunn, W. D., Burgun, A., Krebs, M., & Rance, B. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw080 · Cited by 35
Yu, M., Risacher, S. L., Nho, K. T., Wen, Q., Oblak, A. L., Unverzagt, F. W., Apostolova, L. G., Farlow, M. R., Brosch, J. R., Clark, D. G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113691 · Cited by 36
Self-citationTward, D. J., Sicat, C. S., Brown, T., Bakker, A., Gallagher, M., Albert, M., Miller, M. I., & Initiative, A. D. N. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.07.005 · Cited by 34
Self-citationYee, E., Initiative, A. F. T. A. D. N., ageing, A. T. A. I. B. A. L. F. S. O., Ma, D., Popuri, K., Wang, L., & Beg, M. F. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200830 · Cited by 38
Self-citationZhang, J., Stonnington, C. M., Li, Q., Shi, J., Bauer, R. J., III, Gutman, B. A., Chen, K., Reiman, E. M., Thompson, P. M., Ye, J., et al. (2016) · IEEE International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi.2016.7493350 · Cited by 34
The Alzheimer's Disease Neuroimaging Initiative Clinical Core
Aisen, P. S. S., Donohue, M., Raman, R., Rafii, M. S., Petersen, R. C., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14167 · Cited by 35
Self-citationKließ, M. K., Martins, R., & Connolly, M. P. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.17 · Cited by 33
Multiplane Convolutional Neural Network (Mp-CNN) for Alzheimer’s Disease Classification
(2021) · International journal of intelligent engineering and systems · doi:10.22266/ijies2022.0228.30 · Cited by 32
Tobisch, A., Stirnberg, R., Harms, R., Schultz, T., Roebroeck, A. F., Breteler, M. M. B., & Stöcker, T. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00650 · Cited by 31
The Clinical Course of Early and Late Mild Cognitive Impairment
Lin, S., Lin, P., Lin, Y., Lee, Y., Wang, C., Peng, S.-W., & Wang, P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.685636 · Cited by 34
Marko, D. M., Foran, G., Vlavcheski, F., Baron, D. C., Hayward, G. C., Baranowski, B. J., Necakov, A., Tsiani, E., & MacPherson, R. E. K. (2020) · Cells · doi:10.3390/cells9051114 · Cited by 30
Salvadó, G., Milà‐Alomà, M., Shekari, M., Minguillón, C., Fauria, K., Niñerola‐Baizán, A., Perissinotti, A., Kollmorgen, G., Buckley, C. J., Farrar, G., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12245 · Cited by 30
Aging and APOE ‐ε4 are determinative factors of plasma A β 42 levels
Nakamura, T., Kawarabayashi, T., Seino, Y., Hirohata, M., Nakahata, N., Narita, S., Itoh, K., Nakaji, S., & Shoji, M. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.635 · Cited by 31
Koychev, I. G., Lawson, J., Chessell, T., Mackay, C. E., Gunn, R. N., Sahakian, B. J., Rowe, J. B., Thomas, A. J., Rochester, L., Chan, D., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024498 · Cited by 31
Quantitative Analysis of Synthetic Magnetic Resonance Imaging in Alzheimer’s Disease
Lou, B., Jiang, Y., Li, C., Wu, P., Li, S., Qin, B., Chen, H., Wang, R., Wu, B., & Chen, M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.638731 · Cited by 29
Global EEG coherence as a marker for cognition in older adults at risk for dementia
Laptinskaya, D., Fissler, P., Küster, O. C., Wischniowski, J., Thurm, F., Elbert, T. R., Arnim, C. A. F. V., & Kolassa, I. (2019) · Psychophysiology · doi:10.1111/psyp.13515 · Cited by 30
Operationalising fairness in medical AI adoption: detection of early Alzheimer’s disease with 2D CNN
Heising, L. M., & Angelopoulos, S. P. (2022) · BMJ Health & Care Informatics · doi:10.1136/bmjhci-2021-100485 · Cited by 28
Canu, E., Sarasso, E., Filippi, M., & Agosta, F. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0347-1 · Cited by 26
Yan, Y., Somer, E. J., & Grau, V. (2018) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000953 · Cited by 26
Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia
Sheikh‐Bahaei, N., Sajjadi, S. A., & Pierce, A. L. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0484-z · Cited by 28
Choi, Y. Y., Lee, J. J., Choi, K. Y., Seo, E. H., Choo, I. H., Kim, H., Song, M., Choi, S., Cho, S. H., Kim, B. C., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00233 · Cited by 24
Self-citationTelomere Shortening in the Alzheimer’s Disease Neuroimaging Initiative Cohort
Nudelman, K. N. H., Lin, J., Lane, K. A., Nho, K. T., Kim, S., Faber, K. M., Risacher, S. L., Foroud, T., Gao, S., Davis, J. W., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190010 · Cited by 23
Self-citationFan, Z., Wen, H., Zhang, X., Li, J., & Zang, J. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c06240 · Cited by 24
Su, F., Yuan, P., Wang, Y., & Zhang, C. (2016) · Protein & Cell · doi:10.1007/s13238-016-0302-5 · Cited by 25
The power of knowledge about dementia in Latin America across health professionals working on aging
Ibáñez, A. M., Flichtentrei, D., Hesse, E., Dottori, M., Tomio, A., Slachevsky, A., Serrano, C. M., González-Billault, C. E., Custodio, N., Miranda‐Castillo, C., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12117 · Cited by 23
Xicota, L., Gyorgy, B., Grenier‐Boley, B., Lecoeur, A., Fontaine, G., Danjou, F., Samper‐Gonzàlez, J., Olivier Colliot, A., Amouyel, P., Martin, G., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200544 · Cited by 22
Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia
Eisenmenger, L. B., Huo, E. J., Hoffman, J. M., Minoshima, S., Matesan, M. C., Lewis, D. H., Lopresti, B. J., Mathis, C. A., Okonkwo, D. O., & Mountz, J. M. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.09.003 · Cited by 21
Geng, Z., Wu, X., Wang, L., Zhou, S., Tian, Y., Wang, K., & Wei, L. (2020) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2020.1711873 · Cited by 22
Dong, Q., Zhang, W., Stonnington, C. M., Wu, J., Gutman, B. A., Chen, K., Su, Y., Baxter, L. C., Thompson, P. M., Reiman, E. M., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102338 · Cited by 23
Li, J., Zhang, X., Li, A., Liu, S., Qin, W., Yu, C., Liu, Y., Liu, B., & Jiang, T. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.022 · Cited by 22
Dong, M., Xie, L., Das, S. R., Wang, J., Wisse, L. E. M., de Florès, R., Wolk, D. A., & Yushkevich, P. A. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118514 · Cited by 21
Zhao, L., Wang, Z.-T., Ma, Y., Zhang, W., Dong, Q., Yu, J., Tan, L., & Initiative, A. D. N. (2021) · BMC Neurology · doi:10.1186/s12883-021-02356-9 · Cited by 20
Self-citationGroechel, R. C., Zajac, L., Mian, A. Z., Cervantes-Arslanian, A. M., Steinberg, E. G., Alosco, M. L., Mez, J. B., Stern, R. A., Killany, R., & Initiative, A. D. N. (2019) · Journal of the International Neuropsychological Society · doi:10.1017/s135561771900047x · Cited by 21
Self-citationHarmonizing AI governance regulations and neuroinformatics: perspectives on privacy and data sharing
Alsaigh, R., Mehmood, R., Katib, I. A., Liang, X., Alshanqiti, A. M., Corchado, J., & See, S. (2024) · Frontiers Neuroinformatics · doi:10.3389/fninf.2024.1472653 · Cited by 19
Uysal, G., & Öztürk, M. (2020) · Medical Technologies Congress (TIPTEKNO) · doi:10.1109/tiptekno50054.2020.9299217 · Cited by 21
Chen, Y., Therriault, J., Luo, J., Ba, M., Zhang, H., & Initiative, A. D. N. (2021) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2004088 · Cited by 19
Self-citationMa, K., Yu, J., Shao, W., Xu, X., Zhang, Z., & Zhang, D. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.11.018 · Cited by 22
Suhara, T., Chaki, S., Kimura, H., Furusawa, M., Matsumoto, M., Ogura, H., Negishi, T., Saijo, T., Higuchi, M., Omura, T., et al. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw111 · Cited by 19
Imaging of neurodegenerative cognitive and behavioral disorders
Atri, A. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53486-6.00050-8 · Cited by 19
Guan, J., Wang, P., Lü, L., & Zhao, G. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00038 · Cited by 19
FiboNeXt: Investigations for Alzheimer’s Disease detection using MRI
Tuncer, T., Doğan, Ş., & Subaşı, A. (2024) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2024.107422 · Cited by 18
Raamana, P. R., Strother, S. C., & for the Australian Imaging Biomarkers, L. F. S. O. A. (2020) · Brain Structure and Function · doi:10.1007/s00429-020-02136-0 · Cited by 19
Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies
Choi, Y., Ha, S., Lee, Y., Kim, Y. K., Lee, D. S., & Kim, D. J. (2017) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-017-0484-7 · Cited by 18
Wakasugi, N., & Hanakawa, T. (2021) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2021.777706 · Cited by 17
Network Medicine Approach for Analysis of Alzheimer’s Disease Gene Expression Data
Cohen, D., Pilozzi, A. R., & Huang, X. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010332 · Cited by 17
Zhang, F., Petersen, M. E., Johnson, L. A., Hall, J. R., & O’Bryant, S. E. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.798962 · Cited by 21
Activated Caspase-3 and Neurodegeneration and Synaptic Plasticity in Alzheimer’s Disease
Płóciennik, A., Prendecki, M., Zuba, E. B., Siudzinski, M., & Dorszewska, J. (2015) · Advances in Alzheimer s Disease · doi:10.4236/aad.2015.43007 · Cited by 17
The New Criteria for Alzheimer’s Disease - Implications for Geriatricians*
Molin, P., & Rockwood, K. J. (2016) · Canadian Geriatrics Journal · doi:10.5770/cgj.19.207 · Cited by 22
The Hidden Dangers of Sedentary Living: Insights into Molecular, Cellular, and Systemic Mechanisms
Diniz, D. G., Bento‐Torres, J., da Costa, V. O., Carvalho, J. P. R., Tomás, A. M., de Oliveira, T. C. G., Soares, F. C., de Macedo, L. D. E. D., Jardim, N. Y. V., Bento-Torres, N. V. O., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910757 · Cited by 19
Roussotte, F. F., Hua, X., Narr, K. L., Small, G. W., & Thompson, P. M. (2016) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2016.09.005 · Cited by 16
Kochunov, P. V., Ryan, M. C., Yang, Q., Hatch, K. S., Zhu, A. H., Thomopoulos, S. I., Jahanshad, N., Schmaal, L., Thompson, P. M., Chen, S., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102574 · Cited by 16
System-Level Analysis of Alzheimer’s Disease Prioritizes Candidate Genes for Neurodegeneration
Brabec, J. L., Lara, M. K., Tyler, A. L., & Mahoney, J. M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.625246 · Cited by 18
Choi, Y. Y., Lee, J. J., Choi, K. Y., Seo, E. H., Choo, I. H., Kim, H., Song, M., Choi, S., Cho, S. H., Kim, B. C., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.604238 · Cited by 16
Association of Tau Pathology With Clinical Symptoms in the Subfields of Hippocampal Formation
Ge, X., Zhang, D., Qiao, Y., Zhang, J., Xu, J., & Zheng, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.672077 · Cited by 15
Uysal, G., & Öztürk, M. (2023) · Multimedia Tools and Applications · doi:10.1007/s11042-023-16413-7 · Cited by 16
Pharmacogenomics for neurodegenerative disorders - a focused review
Ahmad, S. R., Zeyaullah, M., Khan, M. S. A. A., AlShahrani, A. M., Altijani, A. A. G., Ali, H., Dawria, A., Mohieldin, A., Alam, M. S., & Mohamed, A. O. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1478964 · Cited by 17
Li, X., Zhu, X., Zhang, W., Yang, F., Hui, J., Tan, J., Xie, H., Peng, D., Ma, L.-H., Cui, L.-Q., et al. (2018) · Aging · doi:10.18632/aging.101548 · Cited by 15
Kaipainen, A. L., Jääskeläinen, O., Liu, Y., Haapalinna, F., Nykänen, N., Vanninen, R. L., Koivisto, A. M., Julkunen, V., Remes, A. M., & Herukka, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200175 · Cited by 15
Inflammation in the CNS: Understanding Various Aspects of the Pathogenesis of Alzheimer's Disease
Doroszkiewicz, J., Mroczko, P., & Kulczyńska‐Przybik, A. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211202143935 · Cited by 14
Bayesian inference and dynamic prediction for multivariate longitudinal and survival data
Zou, H., Zeng, D., Xiao, L., & Luo, S. (2023) · The Annals of Applied Statistics · doi:10.1214/23-aoas1733 · Cited by 14
Jin, C., & Bhaskar, S. M. M. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70246 · Cited by 14
Drug Target Prioritization for Alzheimer's Disease Using Protein Interaction Network Analysis
Podder, A., Pandit, M., & Narayanan, L. (2018) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2018.0131 · Cited by 14
Omar, S. H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809593-5.00004-5 · Cited by 16
Ishibashi, K., Onishi, A., Wagatsuma, K., Fujiwara, Y., & Ishii, K. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002948 · Cited by 14
Head injury is associated with tau deposition on PET in MCI and AD patients
Risacher, S. L., West, J. D., Deardorff, R. L., Gao, S., Farlow, M. R., Brosch, J. R., Apostolova, L. G., McAllister, T. W., Wu, Y., Jagust, W. J., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12230 · Cited by 13
Self-citationGe, X., Initiative, A. D. N., Qiao, Y., Choi, J., Raman, R., Ringman, J. M., & Shi, Y. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215555 · Cited by 14
Self-citationSaraceno, G. F., Abrego-Guandique, D. M., Cannataro, R., Caroleo, M. C., & Cione, E. (2024) · BioMedInformatics · doi:10.3390/biomedinformatics4010033 · Cited by 13
Rajendrakumar, A. L., Arbeev, K. G., Bagley, O., Yashin, A. I., Ukraintseva, S. V., & Initiative, A. D. N. (2024) · BMC Neurology · doi:10.1186/s12883-024-03577-4 · Cited by 15
Self-citationCerebrovascular markers of WMH and infarcts in ADNI: A historical perspective and future directions
Maillard, P., Fletcher, E. M., Carmichael, O. T., Schwarz, C. G., Seiler, S., DeCarli, C. S., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14358 · Cited by 17
Self-citationBit, S., Dey, P., Maji, A., Initiative, A. D. N., & Khan, T. K. (2024) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823241290694 · Cited by 14
Self-citationEffects of transthyretin on thyroxine and β‐amyloid removal from cerebrospinal fluid in mice
Chen, R., Chen, C. P., & Preston, J. E. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12598 · Cited by 13
Semi-Supervised Multimodal Image Translation for Missing Modality Imputation
Sun, W., Ma, F., Li, Y., Huang, S., Ni, S., & Zhang, L. (2021) · IEEE International Conference on Acoustics Speech and Signal Processing · doi:10.1109/icassp39728.2021.9413461 · Cited by 13
Liu, W., Huang, H.-T., Hung, H.-Y., Lin, S., Hsu, W.-H., Lee, F.-Y., Kuan, Y., Lin, Y.-T., Hsu, C.-R., Stettler, M. E. J., et al. (2023) · Life · doi:10.3390/life13030613 · Cited by 13
Yao, X., Yan, J., Ginda, M., Börner, K., Saykin, A. J., Shen, L., & Initiative, A. D. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186095 · Cited by 12
Self-citationvan Zijl, P. C. M., & Knutsson, L. (2019) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2019.07.034 · Cited by 12
Computational analysis of functional SNPs in Alzheimer’s disease-associated endocytosis genes
Tey, H. J., & Ng, C. H. (2019) · PeerJ · doi:10.7717/peerj.7667 · Cited by 11
Sharma, H. S., Muresanu, D. F., Nozari, A., Lafuente, J. V., Buzoianu, A. D., Sahib, S., Tian, Z. R., Bryukhovetskiy, I., Manzhulo, I., Menon, P. K., et al. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.04.008 · Cited by 11
Parekh, P., Bhalerao, G. V., Rao, R., Sreeraj, V. S., Holla, B., Saini, J. S., Venkatasubramanian, G., John, J. P., & Jain, S. (2021) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1871 · Cited by 7
Olatunde, O. O., Oyetunde, K. S., Han, J., Khasawneh, M. T., & Yoon, H. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120929 · Cited by 11
Köksalmış, G. H., Soykan, B., Brattain, L. J., & Huang, H. (2025) · Wiley Interdisciplinary Reviews Computational Statistics · doi:10.1002/wics.70043 · Cited by 12
White, M. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-020-00117-3 · Cited by 10
Wei, Y., Huang, N., Liu, Y., Zhang, X., Wang, S., & Tang, X. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210218150223 · Cited by 10
Associations of Polygenic Risk Score for Late-Onset Alzheimer's Disease With Biomarkers
Li, Q., Lv, X., Jin, F., Liao, K., Gao, L., & Xu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.849443 · Cited by 10
Lizarraga, G., Li, C., Cabrerizo, M., Barker, W., Loewenstein, D., Duara, R., & Adjouadi, M. (2018) · JMIR Medical Informatics · doi:10.2196/medinform.9063 · Cited by 10
An, H., Son, S. J., Cho, S., Cho, E. Y., Choi, B., & Kim, S. Y. (2015) · International Psychogeriatrics · doi:10.1017/s104161021500229x · Cited by 12
Nery, T. G. M., da Silva, E. M. G., Tavares, R., & Passetti, F. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1220-1 · Cited by 10
Peng, D., Xu, S., Zou, T., Wang, Y., Ouyang, W., Zhang, Y., Dong, C., Li, D., Guo, J., Shen, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03126-9 · Cited by 9
Large language models for Alzheimer's disease drug discovery
Alkam, T., Tarshizi, E., & Benschoten, A. H. V. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251346890 · Cited by 9
Wang, K., Yuan, Y., Zhu, B., Zhang, Y., Wei, Y.-F., Meng, F.-S., Zhang, S., Wang, J., Zhou, J., & Initiative, A. D. N. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1277731 · Cited by 8
Self-citationAnalysis of Brain Tissue and Cerebrospinal Fluid Feature for Alzheimer’s Disease Detection
Angkoso, C. V., Purnama, I. K. E., & Purnomo, M. H. (2018) · International Conference on Computer Engineering, Network, and Intelligent Multimedia (CENIM) · doi:10.1109/cenim.2018.8711088 · Cited by 9
Wu, L., Wang, X., Ye, Y., & Liu, C. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.664443 · Cited by 8
Screening for Dementia Caused by Modifiable Lifestyle Choices Using Hybrid PET/MRI
Prato, F. S., Pavlosky, W. F., Foster, S. C., Thiessen, J. D., & Beaujot, R. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-180098 · Cited by 10
Bayahya, A. Y., Banjar, H. R., Talabay, O., & Alamri, S. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-27914-w · Cited by 9
Wang, X., Bi, Q., Lu, J., Chan, P., Hu, X., Su, L., Jessen, F., Lin, H., Han, C., Shu, N., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215373 · Cited by 8
Adenosine Receptors in Alzheimer’s Disease
Canas, P. M., Cunha, R. A., & Agostinho, P. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-90808-3_11 · Cited by 8
Deep learning-based classification of multi-categorical Alzheimer's disease data.
Cohen, D. S., Carpenter, K. A., Jarrell, J. T., & Huang, X. (2019) · PubMed · Cited by 8
Ye, T., Gao, H., Xuan, W.-T., Ye, S., Zhou, P., Li, X., Wang, Y., Song, H., Liu, Y.-Y., & Cai, B. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s245128 · Cited by 8
Shaaban, C. E., Tudorascu, D., Glymour, M. M., Cohen, A. D., Thurston, R. C., Snyder, H. M., Hohman, T. J., Mukherjee, S., Yu, L., & Snitz, B. E. (2022) · Frontiers in Neuroimaging · doi:10.3389/fnimg.2022.978350 · Cited by 9
Biomarkers for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00007-0 · Cited by 9
Metadata
- Authors
- Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Luthman, J., Morris, J. C., Petersen, R. C., Saykin, A. J., Shaw, L., Shen, L., Schwarz, A., Toga, A. W., Trojanowski, J. Q., & Initiative, A. D. N.
- Affiliations
- San Francisco VA Medical Center (US)
- University of California San Diego (US)
- University of California, Davis (US)
- Washington University in St. Louis (US)
- Biogen (United States) (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- University of California, Berkeley (US)
- Eisai (United States) (US)
- Indiana University Indianapolis (US)
- University of Pennsylvania (US)
- Eli Lilly (United States) (US)
- University of Southern California (US)
- Corresponding author
- Weiner, Michael W.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2015-06
- Volume
- 11
- Issue
- 6
- Pages
- e1-120
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC5469297
- OpenAlex
- W1797408175
- Cited by
- 348
- References
- 565
- Citations by year
- 2026: 27 · 2025: 22 · 2024: 28 · 2023: 18 · 2022: 18 · 2021: 43 · 2020: 28 · 2019: 38 · 2018: 36 · 2017: 45 · 2016: 33 · 2015: 11
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Biogen
- Synarc
- TauRx Pharmaceuticals
- Bayer HealthCare
- Servier
- Ipsen
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, P30AG010129, P30AG010133, R01AG012975, R01AG030048, P30AG036468, P30AG010124, P01AG009215, P01AG017586, U01AG010483, U01AG029213, P50AG005681, R01AG016381, P01AG003991, R01AG019771, RC2AG036535, P01AG019724)
- National Cancer Institute (P30CA093373)
- National Institute of General Medical Sciences (R01GM088336)
- National Institute of Neurological Disorders and Stroke (P50NS053488)
- National Center for Research Resources (UL1RR024146, R25RR026008)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Alzheimer Disease, Brain, Humans, Radionuclide Imaging, Multicenter Studies as Topic, Biomarkers, Nootropic Agents, Early Diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
